olmesartan medoxomil + hydrochlorothiazide, if necessary + nitrendipine + hydrochlorothiazide, if necessary
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Isolated Systolic Hypertension
Conditions
Isolated Systolic Hypertension
Trial Timeline
Jul 1, 2003 → Feb 1, 2005
NCT ID
NCT00751829About olmesartan medoxomil + hydrochlorothiazide, if necessary + nitrendipine + hydrochlorothiazide, if necessary
olmesartan medoxomil + hydrochlorothiazide, if necessary + nitrendipine + hydrochlorothiazide, if necessary is a phase 3 stage product being developed by Daiichi Sankyo for Isolated Systolic Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT00751829. Target conditions include Isolated Systolic Hypertension.
What happened to similar drugs?
0 of 1 similar drugs in Isolated Systolic Hypertension were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00751829 | Phase 3 | Completed |
Competing Products
4 competing products in Isolated Systolic Hypertension
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sprifermin (AS902330) 10 mcg + Sprifermin (AS902330) 30 mcg + Sprifermin (AS902330) 100 mcg | Merck | Phase 2 | 27 |
| Rebif® | Merck | Phase 3 | 40 |
| romiplostim | Amgen | Phase 2 | 35 |
| 6R-BH4 | BioMarin Pharmaceutical | Phase 2 | 24 |